Migraine Treatment

被引：16

作者：

Danielle, A. ^{[1
]}

Sawyer, Justin ^{[1
]}

Sommer, Nicole ^{[1
]}

Moore, John B. ^{[2
,3
,4
]}

机构：

[1] Southern Illinois Univ, Inst Plast Surg, 747 North Rutledge St 3, Springfield, IL 62702 USA

[2] Midwest Migraine Surg Ctr, 20375 West 151st St,Suite 370, Olathe, KS 66061 USA

[3] KS Hand Ctr, 20375 West 151st St,Suite 370, Olathe, KS 66061 USA

[4] KU Med Ctr, 3901 Rainbow Blvd, Kansas City, KS 66160 USA

来源：

CLINICS IN PLASTIC SURGERY | 2020年 / 47卷 / 02期

关键词：

Migraine; Migraine headaches; Botulinum toxin type A; Migraine surgery; Migraine trigger zones; TOXIN TYPE-A; BOTULINUM-TOXIN; SURGICAL-TREATMENT; UNITED-STATES; ZYGOMATICOTEMPORAL BRANCH; TRIGEMINAL NERVE; HEADACHE; BURDEN; PREVALENCE; ANATOMY;

D O I：

10.1016/j.cps.2020.01.003

中图分类号：

R61 [外科手术学];

学科分类号：

摘要：

Migraine headaches affect more than 35 million Americans and are ranked the third-highest cause of disability worldwide, resulting in decreased quality of life and serious economic consequences. There are 4 types of migraine headaches: frontal, temporal, occipital, and rhinogenic. Each type has a well-described trigger site. Migraines headaches often are refractory to medical therapy and may respond well to botulinum toxin type A. Migraine surgery is another option to release trigger sites. A systematic review of the migraine surgery literature found an average success rate of 90%, with elimination or greater than 50% improvement of migraine headaches after migraine surgery.

引用

页码：295 / +

页数：10

共 39 条

[1] Botulinum toxin type A (BOTOX) for treatment of migraine headaches: An open-label study [J].

Binder, WJ ;

Brin, MF ;

Blitzer, A ;

Schoenrock, LD ;

Pogoda, JM .

OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 2000, 123 (06) :669-676

[2]

Brin MF, 1997, MUSCLE NERVE, pS146

[3] The Prevalence and Burden of Migraine and Severe Headache in the United States: Updated Statistics From Government Health Surveillance Studies [J].

Burch, Rebecca C. ;

Loder, Stephen ;

Loder, Elizabeth ;

Smitherman, Todd A. .

HEADACHE, 2015, 55 (01) :21-34

[4] Selective inhibition of meningeal nociceptors by botulinum neurotoxin type A: Therapeutic implications for migraine and other pains [J].

Burstein, Rami ;

Zhang, XiChun ;

Levy, Dan ;

Aoki, K. Roger ;

Brin, Mitchell F. .

CEPHALALGIA, 2014, 34 (11) :853-869

[5] The pathophysiology of migraine: implications for clinical management [J].

Charles, Andrew .

LANCET NEUROLOGY, 2018, 17 (02) :174-182

[6] Acupuncture for Migraine Prevention [J].

Da Silva, Arnaldo Neves .

HEADACHE, 2015, 55 (03) :470-473

[7]

Dandy WE, 1931, B JOHNS HOPKINS HOSP, V48, P357

[8] Botulinum toxin: A review of the mode of action in migraine [J].

Do, T. P. ;

Hvedstrup, J. ;

Schytz, H. W. .

ACTA NEUROLOGICA SCANDINAVICA, 2018, 137 (05) :442-451

[9] Migraine [J].

Dodick, David W. .

LANCET, 2018, 391 (10127) :1315-1330

[10] OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Results From the Double-Blind, Randomized, Placebo-Controlled Phases of the PREEMPT Clinical Program [J].

Dodick, David W. ;

Turkel, Catherine C. ;

DeGryse, Ronald E. ;

Aurora, Sheena K. ;

Silberstein, Stephen D. ;

Lipton, Richard B. ;

Diener, Hans-Christoph ;

Brin, Mitchell F. .

HEADACHE, 2010, 50 (06) :921-936

← 1 2 3 4 →